Antiepileptic medications increase osteoporosis risk in male fabry patients: Bone mineral density in an australian cohort

JIMD Reports

Volumn 17, Issue , 2014, Pages 29-36

  Talbot, Andrew ^a   Ghali, Joanna R ^a   Nicholls, Kathy ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bone mineral density; Enzyme replacement therapy; Fabry disease; Femoral neck; Renal replacement therapy

Indexed keywords

EID: 84973129076     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2014_328     Document Type: Chapter

References (29)

1. Blake GM, Fogelman I (2009) The clinical role of dual energy X-ray absorptiometry. Eur J Radiol 71:406–414
2. Desnick RJ, Brady R, Barranger J et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346
3. Drake MT, Murad MH, Mauck KF et al (2012) Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocr Metab 97:1861–1870
4. Ebeling P (2008) Osteoporosis in men. New Engl J Med 358:1474–1482
5. Ferrari S, Bianchi ML, Eisman JA et al (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporosis Int 23:2735–2748
6. Germain DP (2010) Bone and muscle involvement in fabry disease. In: Elstein D, Altarecu G, Beck M (eds) Fabry disease. Chap 16, pp 293–298
7. Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30
8. Germain DP, Benistan K, Boutouyrie P, Mutschler C (2005) Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet 68:93–95
9. Hauser AC, Gessl A, Harm F et al (2005) Hormonal profile and fertility in patients with Anderson–Fabry disease. Int J Clin Pract 59:1025–1028
10. Hofbauer LC, Hamann C, Ebeling PR (2010) Approach to the patient with secondary osteoporosis. Eur J Endocrinol 162:1009–1020
11. International Society of Clinical Densitometry (ISCD) (2013) Official positions of the International Society of Clinical Densitometry: updated 2013. www.iscd.org/official-positions/2013-iscd-official-positions-adult
12. Isenor JE, Ensom MH (2010) Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk? Pharmacotherapy 30:254–264
13. Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194
14. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis Int 4:368–381
15. Kanis JA, Bianchi G, Bilezikian P et al (2011) Towards a diagnostic consensus in male osteoporosis. Osteoporosis Int 22:2789–2798
16. Lips P, Bouillon R, van Schoor NM et al (2010) Reducing fracture risk with calcium and vitamin D. Clin Endocrinol 73:277–285
17. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone density predict occurrence of osteoporotic fracture. Brit Med J 312:1254–1259
18. Mehta A, Clarke JTR, Giugliani R, on behalf of the FOS Investigators et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. J Med Genet 46:548–552
19. Mersebach H, Johansson J-O, Rasmussen A et al (2007) Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med 9:812–818
20. Montalcini T, Romeo S, Ferro Y, Migliaccio V, Gazzaruso C, Pujia A (2013) Osteoporosis in chronic inflammatory disease; the role of malnutrition. Endocrine 43:59–64
21. Nakken KO, Taubøll E (2010) Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf 9:561–571
22. Nishizawa Y, Ohta H, Miura M et al (2013) Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 31:1–15
23. Pack AM, Reddy DS, Duncan S, Herzog A (2011) Neuroendocrino-logical aspects of epilepsy: Important issues and trends in future research. Epilepsy Behav 22:94–102
24. Petty SJ, O’Brien TJ, Wark JD (2007) Anti-epileptic medication and bone health. Osteoporosis Int 18:129–142
25. Ross G, Kuwamura GA (1993) Association of Fabry’s disease with femoral head avascular necrosis. Orthopedics 16:471–473
26. Stone KL, Seeley DG, Lui L-Y et al (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 18:1947–1954
27. Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F (2010) Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosur 112:1–10
28. von Scheidt W, Eng CM, Fitzmaurice TF et al (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324:395–399
29. Zarate YA, Hopkin RJ (2008) Lysosomal storage disease 3: Fabry’s disease. Lancet 372:1427–1435